All content for In Re: is the property of inrecontrolrisks and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Life Science Series: Risks for multinational pharmaceuticals in India
In Re:
13 minutes 25 seconds
1 year ago
Life Science Series: Risks for multinational pharmaceuticals in India
India is an important market for many multinational pharmaceutical, biotech or medical device companies. But it is also a challenging one.
Join Martina Rozumberkova for a conversation with Sushmit Bhattacharya about challenges facing multinational pharmaceutical companies operating in India, from important regulatory changes, including the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, to emerging fraud schemes, including fraud in the Government e-Marketplace (GeM) and retailer incentive schemes.